Clinical trial
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes…
NCT00327626 · Ionis Pharmaceuticals, Inc., Industry · Withdrawn
Key facts
| NCT number | NCT00327626 |
|---|---|
| Title | Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea |
| Official title | A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of ISIS 113715 Administered Daily in Patients With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea |
| Lead sponsor | Ionis Pharmaceuticals, Inc., Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | ISIS 113715 |
| Enrollment | 0 |
| Start date | May 1, 2006 |
| Primary completion | Feb 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | May 18, 2006 |
| Last update posted | Dec 5, 2022 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: